LumiThera Inc is a medical device company currently focused on developing a non-invasive Photobiomodulation therapy for ocular (eye) disorders and disease. Their pilot product LightSite I provided great results after their first clinical trial for the ‘treatment of dry age-related macular degeneration (AMD) utilizing its LT-300 Light Delivery System’.
The results from the clinical trial was presented at the 2018 Association for Research in Vision and Ophthalmology (ARVO) annual conference by members of the LumiThera investigation team. The team consisted of: Marion Munk, MD, PhD, Department of Ophthalmology/Bern Photographic Reading Center and Managing Director, Bern Photographic Reading Center, University Hospital Bern.
“LumiThera PBM treatment demonstrated reductions in central drusen volume over the course of the one-year study versus the sham treatment with statistical significance at one year, (p = 0.05). Drusen is the hallmark pathology of dry AMD and is an important proinflammatory mediator and marker for disease progression,” says Dr. Munk.
“Results from the LIGHTSITE I study following treatment with a multi-wavelength PBM treatment demonstrated clinical improvements in vision outcome measures providing a strong foundation for initial therapy as well as the need for follow-up maintenance therapy,” stated Samuel Markowitz, M.D., Co-Principal Investigator, Department of Ophthalmology and Vision Sciences, University of Toronto. “The PBM therapy was most beneficial in dry AMD patients immediately following the completion of the treatment sessions. Contrast sensitivity or detailed vision was significantly improved throughout the year. Retreatments at a 6 month interval were performed to maintain clinical benefits.”
LumiThera Light Site
LT-300 LED ophthalmologic instrument station provides a multi-wavelength approach to treating ocular disease.
“We are excited by the completion of the LIGHTSITE I trial and seeing the benefits in both clinical outcomes and drusen pathology,” stated Clark Tedford, Ph.D., LumiThera President and CEO. “The LT-300 Light Delivery System performance was excellent throughout the clinical trial and patients provided positive feedback from their PBM treatment experience over the course of a year. This foundational data will accelerate our learning to develop options to treat complicated degenerative eye disease, where patient options are limited. The results demonstrate that the therapy is both a safe and effective treatment for early stage dry AMD patients. The current trial results will be used to refine the upcoming multi-center clinical trials expected to start initially in Europe.”
“LumiThera’s LIGHTSITE I data is the first prospective, sham controlled, double-masked, pilot clinical dry AMD study with PBM,” says Dr. Robert Devenyi, Co-Principal Investigator, Ophthalmologist-in-Chief and Director of Retinal Services, UHN, University of Toronto. “The results show PBM using the LT-300 device can improve Visual Acuity and Contrast Sensitivity as vision endpoints for dry AMD patients to counteract the degradation in vision that this disabling disease brings.”
The pilot study consisted of 30 people and was partially funded by a grant from a Small Business Innovation Research fund, awarded to LumiThera from the National Institute of Health and the National Eye Institute. The clinical trial tested each person’s vision and examined disease pathology in the eye, following PBM treatments for up to one year.
Visit the Company’s website at www.lumithera.com.
About LumiThera Inc.
LumiThera is a clinical-stage medical device company focused on treating people affected by ocular disorders and diseases including dry age-related macular degeneration, a leading cause of blindness in adults over 65. The Company is a leader in the use of Photobiomodulation for treatment of acute and chronic ocular diseases and disorders. The Company is developing the office-based LT-300 Light Delivery System to be used by ophthalmologists and other eye specialists as non-invasive medical treatments.
Important to note: The LT-300 is not yet approved for use by the Food & Drug Administration in the USA. The device has also not yet been granted a CE Mark by a Notified Body for commercial use outside of the USA.
The LT-300 LED ophthalmologic instrument station is designed to provide a multi-wavelength approach to treating ocular disease.
Working research and clinical units are being built to support ongoing research and development activities.